CG Oncology CGON Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -4,239%+16,063pp | -4,722.1%+5,345pp | -8,285.3%+5,746pp | -28,546.1%— | -20,302.3%— | |
| Net margin | -3,682.6%+12,263pp | -3,985%+3,744pp | -6,968%+3,675pp | -23,245.2%— | -15,945.2%— | |
| EBITDA margin | -4,194.4%+16,100pp | -4,686.4%+5,378pp | -8,257.9%+5,768pp | -28,509.6%— | -20,294.4%— | |
| Free cash flow margin | -3,163.8%— | -3,279.2%— | -5,387.7%— | —— | —— | |
| Returns | ||||||
| Return on equity | -20.8%— | -21.7%— | —— | —— | —— | |
| Return on assets | -20%— | -20.8%— | -23.6%— | —— | —— | |
| Return on invested capital | -24.9%— | -31.7%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 31.3×+0.3× | 24.6×-10.7× | 22.8×-12.5× | 22.2×— | 31×— | |
| Quick ratio | 31.3×+0.3× | 24.6×-10.7× | 22.7×-12.6× | 22.2×— | 31×— | |
| Cash ratio | 1×-0.9× | 1.1×-11.0× | 1.5×-1.3× | 0.5×— | 1.8×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $12.92+39.6% | $9.74-17.0% | $8.96+12.1% | $8.79+6.1% | $9.25-23.5% | |
| Valuation | ||||||
| Market capitalization | $5.71B+206% | $3.35B+53.4% | $3.07B— | $1.97B— | $1.87B— | |
| Enterprise value | $5.69B+212% | $3.32B+72.5% | $3.03B— | $1.95B— | $1.83B— | |
| Price / sales | 1,126.9×-1,693× | 829×-1,088× | 1,412.7×— | 3,569.2×— | 2,819.6×— | |
| Price / book | 5.2×+2.6× | 4.5×+1.5× | 4.5×— | 2.9×— | 2.6×— | |
| EV / sales | 1,121.8×-1,637× | 822.7×-869× | 1,395.3×— | 3,544.4×— | 2,758.5×— | |
| Free cash flow yield | -2.8%— | -4%— | -3.8%— | —— | —— | |
| Earnings yield | -3.3%+2.4pp | -4.8%-0.8pp | -4.9%— | -6.5%— | -5.7%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CG Oncology's ratios come from?
- Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.